Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Smallcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cohance Lifesciences Limited has filed its financial results with the stock exchange for the quarter and full year ended March 31, 2025. The filing itself is a routine regulatory compliance step under SEBI listing requirements, but the actual numbers and auditor observations are not included in this notice. Investors will need to review the detailed results document and the auditor's report to assess performance, profitability, margins, and any audit qualifications. Until the detailed results are examined, no specific financial conclusions can be drawn from this announcement alone.
This is a procedural filing notice with no direct impact on share price. Shareholders should look at the actual financial results and auditor's report for any material information on revenue, profit, margins, or audit qualifications.